Comprehensive molecular characterization of pediatric radiation-induced high-grade glioma

John DeSisto(Morgan Adams Foundation), John T. Lucas(St. Jude Children's Research Hospital), Ke Xu(St. Jude Children's Research Hospital), Andrew M. Donson(Morgan Adams Foundation), Tong Lin(St. Jude Children's Research Hospital), Bridget Sanford(Morgan Adams Foundation), Gang Wu(St. Jude Children's Research Hospital), Quynh T. Tran(St. Jude Children's Research Hospital), Dale J. Hedges(St. Jude Children's Research Hospital), Chih‐Yang Hsu(St. Jude Children's Research Hospital), Gregory T. Armstrong(St. Jude Children's Research Hospital), Michael Arnold(Nationwide Children's Hospital), Smita Bhatia(St. Jude Children's Research Hospital), Patrick Flannery(Morgan Adams Foundation), Rakeb Lemma(Morgan Adams Foundation), Lakotah Hardie(Children's Hospital Colorado), Ulrich Schüller(Universität Hamburg), Sujatha Venkataraman(Morgan Adams Foundation), Lindsey M. Hoffman(Morgan Adams Foundation), Kathleen Dorris(Morgan Adams Foundation), Jean M. Mulcahy Levy(Morgan Adams Foundation), Todd C. Hankinson(Morgan Adams Foundation), Michael H. Handler(Morgan Adams Foundation), Arthur K. Liu(Children's Hospital Colorado), Nicholas K. Foreman(Morgan Adams Foundation), Rajeev Vibhakar(Morgan Adams Foundation), Kenneth L. Jones(Morgan Adams Foundation), Sariah J. Allen(St. Jude Children's Research Hospital), Jinghui Zhang(St. Jude Children's Research Hospital), Suzanne J. Baker(St. Jude Children's Research Hospital), Thomas E. Merchant(St. Jude Children's Research Hospital), Brent A. Orr(St. Jude Children's Research Hospital), Adam L. Green(Morgan Adams Foundation)
Nature Communications
September 20, 2021
Cited by 62Open Access
Full Text

Abstract

Radiation-induced high-grade gliomas (RIGs) are an incurable late complication of cranial radiation therapy. We performed DNA methylation profiling, RNA-seq, and DNA sequencing on 32 RIG tumors and an in vitro drug screen in two RIG cell lines. We report that based on DNA methylation, RIGs cluster primarily with the pediatric receptor tyrosine kinase I high-grade glioma subtype. Common copy-number alterations include Chromosome (Ch.) 1p loss/1q gain, and Ch. 13q and Ch. 14q loss; focal alterations include PDGFRA and CDK4 gain and CDKN2A and BCOR loss. Transcriptomically, RIGs comprise a stem-like subgroup with lesser mutation burden and Ch. 1p loss and a pro-inflammatory subgroup with greater mutation burden and depleted DNA repair gene expression. Chromothripsis in several RIG samples is associated with extrachromosomal circular DNA-mediated amplification of PDGFRA and CDK4. Drug screening suggests microtubule inhibitors/stabilizers, DNA-damaging agents, MEK inhibition, and, in the inflammatory subgroup, proteasome inhibitors, as potentially effective therapies.


Related Papers

No related papers found

Powered by citation graph analysis